

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 425 964 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

09.06.2004 Bulletin 2004/24

(51) Int Cl.7: **A01K 67/027**, G01N 33/15,

G01N 33/50

(21) Application number: **02758860.7**

(86) International application number:

PCT/JP2002/008373

(22) Date of filing: **20.08.2002**

(87) International publication number:

WO 2003/017756 (06.03.2003 Gazette 2003/10)

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR**

• **ASAMOTO, Makoto**

Nagoya-shi, Aichi 467-0004 (JP)

• **HOKAIWADO, Naomi; Room 306,**

Nagoya-shi, Aichi 466-0 045 (JP)

(30) Priority: **23.08.2001 JP 2001253241**

(71) Applicant: **Japan Science and Technology
Agency**

Kawaguchi-shi, Saitama 332-0012 (JP)

(74) Representative: **Holliday, Louise Caroline**

D Young & Co,

21 New Fetter Lane

London EC4A 1DA (GB)

(72) Inventors:

• **SHIRAI, Tomoyuki**

Nagoya-shi, Aichi 458-0003 (JP)

(54) **RAT HIGHLY SENSITIVE TO CARCINOGEN**

(57) In order to make it possible to detect a carcinogen highly sensitively and more easily in a short time, the present invention provides a rat having a high sensitivity to a carcinogen, and a method for detecting carcinogens using the rat, and a method for screening anticancer substances using the rat made to develop a cancer. It has been found that a rat whose normal function in gap junction is inhibited has a high sensitivity to a carcinogen. For the inhibition of normal function in gap junction, part of a connexin gene is made to be deficient

and a plasmid vector engineered to carry a gene deficient in connexin function is introduced into a rat to make a transgenic rat. By using the rat of the present invention, it becomes possible to detect a carcinogen highly sensitively and more easily in a short time, and the rat of the present invention made to develop a cancer can be effectively used for the screening of anticancer substances.

EP 1 425 964 A1

Description**Technical Field**

5 **[0001]** The present invention relates to a rat having a high sensitivity to a carcinogen, in particular, a rat having a high sensitivity to a carcinogen whose normal function in gap junction is inhibited, a method for producing the rat and use thereof.

Background Art

10 **[0002]** Gap junction, a structure wherein intercalated disks connected to plasma membranes of contiguous cells are juxtaposed to each other and thereby junctions of intercellular gaps are apparently adhered, is found in many cells/tissues. It is presumed that gap junction is responsible for intercellular communication wherein an intracellular signal transmitter is delivered to a contiguous cell, and serves to maintain the homeostasis of cell proliferation in multicellular
15 organisms. Cell canceration can be regarded as cell proliferation which deviates from homeostasis in normal cells, and it is thought that inhibition of gap junctional function plays an important role in cell canceration ("Experimental Medicine" Vol. 11, No. 16, 28-33, 1993; Histol. Histopathol. 12, 761-768, 1997).

[0003] For example, it is presumed that even though a gene in a certain cell mutates and consequently there is a cell at the early stage of canceration (an initiation cell), if the intercellular communication ability of the cell directed to
20 surrounding normal cells is maintained, the characteristic expression of the initiation cell as a cancerous cell is inhibited, and as a result, the progress of carcinogenesis process is inhibited. In fact, it is known that about 60% of about 300 kinds of carcinogens and cancer promoters inhibit intercellular communication ability in *in vitro* system using cells. Further, decrease of connexin protein expression is observed in carcinogenesis process of various organs of human, rat and mouse, and it is presumed that the abnormality in gap junction is greatly involved in carcinogenesis.

25 **[0004]** Gap junction is an intercellular channel comprised of a pair of hemichannels formed by each of the contiguous cells, that is, a pair of connexons. The connexon has a structure wherein a bridge is formed by a cylindrical protein which penetrates into an intercalated disk connected to a plasma membrane of a contiguous cell. This channel has a function to deliver substances with molecular weight up to about 1 kD from the inside of a cell to that of a contiguous cell. The connexon is comprised of an assembly of six proteins called connexin. There are many kinds of connexins,
30 and 12 different connexin cDNAs have been cloned so far. Connexins are designated based on the size of proteins they encode, and called, for instance, connexin 26, connexin 32 (Seq. ID No. 2), and connexin 43 (cx26, cx32, and cx43), respectively ("Experimental Medicine" Vol. 11, No. 16, 28-33, 1993).

[0005] A mouse deficient in connexin 32 gene, mainly expressed in the liver, has been already produced and reported by a German group (CANCER RESEARCH, 60, 5087-5091, 2000; Carcinogenesis vol. 20, no. 7, 1379-1382, 1999;
35 Current Biology, 7, 713-716, 1997). However, mice are originally less responsive than rats to hepatocarcinogens and hepatocarcinogenesis modifiers.

[0006] Meanwhile, there exists glutathione S-transferase placental form (GST-P) as a precancerous hepatic lesion marker in rats, and therefore, a precancerous lesion as an object of analysis can be measured efficiently in a short time. By contrast, there is no precancerous lesion marker for mice, such as GST-P for rats. ES cells of rats have not
40 been established yet and it is impossible to produce a gene-deficient rat.

[0007] The object of the present invention is to provide a rat having a high sensitivity to a carcinogen, a method for detecting carcinogens using the rat, and a method for screening anticancer substances using the rat made to develop a cancer in order to make it possible to detect a carcinogen highly sensitively and more easily in a short time.

[0008] In order to attain the above-mentioned object, the present inventors have conducted keen study and found
45 that a rat whose normal function in gap junction, in particular, channel function of connexon, is inhibited, has a high sensitivity to a carcinogen, and thus the present invention has been completed. As for the inhibition of channel function of connexon, part of a connexin gene is made to be deficient and a plasmid vector engineered to carry a gene deficient in connexin function is introduced into a rat to make a transgenic rat. By using the rat of the present invention, it becomes possible to detect a carcinogen highly sensitively and more easily in a short time, and the rat of the present invention
50 made to develop a cancer can be effectively used for the screening of anticancer substances.

Disclosure of the Invention

55 **[0009]** The present invention relates to a rat highly sensitive to a carcinogen whose normal function in gap junction is inhibited (claim 1), the rat highly sensitive to a carcinogen according to claim 1, wherein the inhibition of the normal function in gap junction is an inhibition of channel function of connexon (claim 2), the rat highly sensitive to a carcinogen according to claim 2, wherein the inhibition of channel function of connexon is based on a deficiency of connexin function (claim 3), and the rat highly sensitive to a carcinogen according to claim 3, wherein the deficiency of connexin

function is based on amutation of connexin 32 (claim 4).

[0010] The present invention also relates to a method for producing a rat highly sensitive to a carcinogen comprising the steps of: constructing a plasmid vector engineered to carry mutated rat connexin cDNA downstream of a promoter, and microinjecting the plasmid vector into a fertilized egg and then transplanting the fertilized egg into an oviduct (claim 5), the method for producing a rat highly sensitive to a carcinogen according to claim 5, wherein the promoter is an albumin promoter and the mutated rat connexin cDNA is a cDNA that encodes an amino acid sequence of rat connexin 32 wherein part of an amino acid is deleted (claim 6), a method for detecting a carcinogen wherein a test substance is administered to the rat highly sensitive to a carcinogen according to any one of claims 1 to 4 (claim 7), a method for screening an anticancer substance wherein a test substance is administered to a rat made to develop a cancer by using the rat highly sensitive to a carcinogen according to any one of claims 1 to 4 (claim 8), and the method for screening an anticancer substance according to claim 8, wherein carcinogenesis of the rat highly sensitive to a carcinogen is caused by the administration of a carcinogen (claim 9).

Brief Description of Drawings

[0011]

Fig. 1 is a view showing a plasmid vector Cx32/pGEM-Alb engineered to carry a gene connected to rat connexin 32 cDNA (GeneBank, NM017251) downstream of an albumin promoter, being used in the present invention.

Fig. 2 is a view showing the result of transgene expression confirmed by RT-PCR in total RNA extracted from a transgenic rat (baby rat) produced by the method of the present invention.

Fig. 3 comprises photographs showing the results of fluorescent microscopic observation using immunofluorescent staining of localization of connexin 32 in the livers of a transgenic rat and a wild-type rat of the present invention.

Fig. 4 comprises a photograph of an immunostained precancerous hepatic lesion marker resulted from 20-week observation after administering diethyl nitrosoamine to a transgenic rat and a wild-type rat of the present invention, and a photograph showing measurement results of the number and area of foci per unit area in the lesion.

Fig. 5 is a view showing the result that a transgenic rat exhibits much higher expression in comparison to the expression of CYP1A1 and CYP1A2 in the livers of a transgenic rat (Tg) and a wild-type rat (Wild) of the present invention.

Best Mode of Carrying Out the Invention

[0012] The present invention comprises the production of a rat whose normal function in gap junction is inhibited, in particular, the production of a rat whose channel function of connexon in gap junction is inhibited. So far, ES cells of rats have not been established yet and it is impossible to produce a gene-deficient rat. However, as to connexon, whose channel is formed by connexin molecule hexamers, the function of normal connexin does not express since channel function will be inhibited if any one of the hexamers is a mutant connexin. Therefore, a rat whose normal function in gap junction is inhibited can be produced by producing a transgenic rat having a mutant connexin gene.

[0013] There is no particular limitation as to the mutant connexin gene, but mutant connexin 32 gene wherein the function of normal connexin does not express can be advantageously used. Various methods for mutation can be used to produce mutant connexin wherein the function of normal connexin does not express, however, a method using cDNA wherein part of a gene encoding connexin is made to be deficient can be advantageously used. In a transgenic rat mutated by a mutant connexin 32 gene wherein the function of normal connexin does not express, gap junction having normal function is not formed in hepatocytes because there is mutant connexin 32, and the expression of a mutant character by surrounding normal cells through gap junction is not controlled sufficiently in initiated cells. Consequently, a precancerous lesion is in a more advantageous proliferation environment and therefore it expresses a character highly sensitive to a carcinogen.

[0014] In order to introduce a mutated rat connexin gene into a rat in the present invention, appropriate methods employed in this field can be used, however, a method comprising the steps of: constructing a plasmid vector engineered to carry mutated rat connexin cDNA downstream of a promoter, and injecting the plasmid vector into a fertilized egg and then transplanting the fertilized egg into an oviduct can be advantageously used. The promoter is not particularly limited, but an albumin promoter is particularly preferable. A transgenic rat can be obtained by the method comprising the following steps: constructing a plasmid vector engineered to carry rat connexin cDNA mutated by, for example, deleting part of an amino acid, downstream of this promoter, and injecting this plasmid vector into a male pronucleus of a rat fertilized egg and then transplanting the fertilized egg into an oviduct of a female being false pregnant.

[0015] The rat of the present invention is used to detect carcinogens. That is, the rat highly sensitive to a carcinogen of the present invention is administered with a test substance and then carcinogens are detected. The method for administering a test substance and the method for detecting carcinogens are not particularly limited and methods

usually employed in this field are used. Further, in the present invention, it is possible to screen anticancer substances by administering a test substance to an individual made to develop a cancer by using the rat highly sensitive to a carcinogen of the present invention. For carcinogenesis in rat, carcinogens can be used. The method for administering a test substance and the method for detecting anticancer substances are not particularly limited and methods usually employed in this field are used.

[0016] The present invention will be described more specifically with examples, but the scope of the present invention is not limited to these examples.

Example 1 (Construction of transgene)

[0017] A plasmid vector Cx32/pGEM-Alb engineered to carry a gene connected to rat connexin 32 cDNA (GeneBank, NM017251: Seq. ID No. 1) downstream of an albumin promoter was provided by Dr. Hiroshi Yamasaki (IARC, Lyon, Kwasei Gakuin University, School of Science). The amino acids in the 113th to 124th position of this connexin 32 cDNA were deleted, and further, for a marker to be used after the introduction of this gene, a construct to which six histidines are inserted at the position immediately before the termination codon (Seq. ID No. 3) was made with the use of Ex-Site-PCR-Based Site-Directed Mutagenesis Kit (Stratagene) (Fig. 1). This construct was cut out from a plasmid moiety at Apa I and Mlu I, and used as a transgene.

Example 2 (Production of transgenic rat)

[0018] Baby rats were obtained by the method comprising the following steps: microinjecting the above-mentioned transgene into a male pronucleus of a fertilized egg of SD rat, culturing the obtained egg cell, and then transplanting the fertilized egg into an oviduct of a female being false pregnant. DNA was extracted from a tail part of the obtained babies, and the transgene was confirmed by PCR using primer 1 (5'-AACGTGGCGCAGGTGGTGTGA-3'; Seq. ID No. 4: P1) and primer 2 (5'-ATGGTGATGGTGATGATGGC-3'; Seq. ID No. 5: P2) for the transgene, and primer 3 (5'-GGGAAGGTTTGATGGAGTAAT-3'; Seq. ID No. 6: P3) for endogenous connexin 32 (cx32). The primer 2 corresponds to the introduced histidine, and PCR product can be obtained only when both the transgene and the primer 1 exist. In addition, in order to search the expression of the transgene in the liver, total RNA was extracted from the liver and RT-PCR was conducted (Fig. 2). In Fig. 2, Tg-H means a strain of transgenic rats with high expression of the transgene, Tg-G means a strain of transgenic rats with low expression of the transgene, and Wild means wild-type rat (SD rat), respectively. As a result, it was confirmed that the transgene existed in five rats in total, and that four of them transmitted the transgene to the next generation, and that mRNA of the transgene was expressed in the livers of two strains of them. A strain with higher expression was selected from the two strains and used for the following examples. The transgenic rats used for the following examples were obtained by intercrossing male transgenic rats and female wild-type SD rats.

Example 3 (Immunofluorescent staining of connexin 32)

[0019] Frozen sections of the livers of the transgenic rats and wild-type rats obtained in Example 3 were fixed with acetone at -20° C for five minutes and followed by air-drying, and then blocked by treating with methanol/H₂O₂. The frozen sections were incubated in the coexistence of anti-connexin 32 rabbit polyclonal antibody (Zymed), followed by immunofluorescent staining with biotinylated anti-rabbit IgG antibody (Vector) and FITC-labeled streptavidin (Vector), then the localization was observed by a fluorescent microscope (AX7C; Olympus). As a result, in the livers of wild-type rats, a number of spotlike localization of connexin 32 was observed on the membranes of contiguous hepatocytes. Meanwhile, no clear localization of connexin 32 was found in the livers of transgenic rats. Thus, it was confirmed that spotlike localization of normal endogenous connexin 32 on the membrane was inhibited by the expression of connexin 32 that had been introduced (Fig. 3).

Example 4 (Measurement of intercellular communication ability between hepatocytes)

[0020] After extracting the liver from a rat, the liver was sliced into pieces about 5 mm thick, and a vertical cut about 1 mm deep was made on the sliced face with a knife. A sufficient amount of 0.05% lucifer yellow was dropped on the cut and the slice was kept still for three minutes, then washed three times with PBS, and embedded in OTC compound (TissuTek, Miles), then frozen. A frozen section of 6 μm thick was made by cryostat and the spread of fluorescence was observed under a fluorescent microscope. From this observation, it has been revealed that in the livers of wild-type rat, the fluorescence taken up through the cells damaged by the knife widely spread to the surrounding hepatocytes by intercellular communication through gap junction. On the other hand, in the livers of transgenic rats, the spread of fluorescence was obviously in low level, and it has been revealed that intercellular communication ability was inhibited.

Example 5 (Search of sensitivity to hepatocarcinogenesis by diethyl nitrosamine)

[0021] 200 mg/kg diethyl nitrosamine was intraperitoneally administered to eight-week-old male transgenic rats or wild-type rats, and the rats were observed for 20 weeks after the administration, and then slaughtered and dissected. The livers taken from each of the above-mentioned rats were fixed with acetone and embedded in paraffin, sliced, and then GST-P, a precancerous hepatic lesion marker, was immunostained for visualization (Fig. 4, left). Further, the number and the area of positive foci per unit area in the GST-P-positive foci were measured with an image analyzer (IPAP, Olympus) (Fig. 4, right). As a result of these observations, the number and the area of the GST-P-positive foci, which is precancerous foci, per unit area (1 cm²) in the transgenic rats were remarkably increased in comparison to those in wild-type rats, that is, the number was 11.1 for wild-type rats and 79.8 for the transgenic rats, and the area was 0.2 mm² for the wild-type rats and 3.32 mm² for the transgenic rats. Therefore, it has been found that these transgenic rats exhibit an extremely high sensitivity to diethyl nitrosamine, a hepatocarcinogen.

Example 6 (Liver-specific gene expression of transgenic rat by cDNA array and RT-PCR)

[0022] Total RNA was extracted from the livers of male transgenic rats and wild-type rats by ISOGEN (NIPPON GENE), and the changes in the expression of each gene were searched by using Atlas rat toxicology array (Clontech).

[0023] Based on the results, according to the search with cDNA array, genes of drug-metabolizing enzymes such as various molecular species of cytochrome p450 (CYP) and glutathion S-transferase (GST) were fixed as a gene that shows changes in the expression in the transgenic rats compared to that in the wild-type rats. Then, changes in the expression of various molecular species of CYP and GST were examined by quantitative RT-PCR using LightCycler (Roche). According to this examination, the clearest change was that CYP1A1 and CYP1A2 were expressed highly in the livers of transgenic rats (Fig. 5). These enzymes contribute to metabolic activation of many carcinogens including diethyl nitrosamine, and are thought to be one mechanism of increasing the sensitivity of transgenic rats to hepatocarcinogenesis. Conventionally, inhibition of intercellular communication ability has been considered to be deeply involved in the promotion activity of carcinogenesis, and this experimental result further reveals that inhibition of intercellular communication ability affects the expression of drug-metabolizing enzymes, and makes a situation wherein carcinogens tend to be metabolically activated.

Industrial Applicability

[0024] The rat whose normal function in gap junction is inhibited of the present invention has a high sensitivity to a carcinogen, and makes it possible to detect a carcinogen highly sensitively and more easily in a short time. In addition, the transgenic rat of the present invention made to develop a cancer shows extremely high degree of usefulness, for example, it can be used effectively for the screening of anticancer substances.

SEQUENCE LISTING

5

<110> JAPAN SCIENCE AND TECHNOLOGY CORPORATION

10

<120> Carcinogen-hypersensitive rat

<130> A031-43PCT

15

<140>

<141>

20

<150> JP P2001-253241

<151> 2001-08-23

25

<160> 6

<170> PatentIn Ver. 2.1

30

<210> 1

<211> 1485

<212> DNA

<213> Rattus norvegicus

35

<220>

<221> CDS

<222> (32)..(883)

40

<400> 1

cgcagtgcca gggagggtgtg aatgaggcag g atg aac tgg aca ggt cta tac 52

45

Met Asn Trp Thr Gly Leu Tyr

1

5

50

acc ttg ctc agt ggc gtg aat cgg cat tct aca gcc att ggc cga gta 100

Thr Leu Leu Ser Gly Val Asn Arg His Ser Thr Ala Ile Gly Arg Val

10

15

20

55

tgg ctg tcc gtc atc ttt atc ttc aga atc atg gtg ctg gtg gtg gct 148

EP 1 425 964 A1

	Trp Leu Ser Val Ile Phe Ile Phe Arg Ile Met Val Leu Val Val Ala	
	25 30 35	
5		
	gca gag agc glg tgg ggt gat gag aag tct tct ttc atc tgt aac acc	196
	Ala Glu Ser Val Trp Gly Asp Glu Lys Ser Ser Phe Ile Cys Asn Thr	
10	40 45 50 55	
	cic cag ccg ggc tgt aac agc glc tgc tat gac cat ttt ttc ccc atc	244
	Leu Gln Pro Gly Cys Asn Ser Val Cys Tyr Asp His Phe Phe Pro Ile	
15	60 65 70	
	tcc cat gtg cgc ctg tgg tcc ctg caa ctc atc ttg gtt tcc acc cca	292
	Ser His Val Arg Leu Trp Ser Leu Gln Leu Ile Leu Val Ser Thr Pro	
20	75 80 85	
	gcl ctc ctc glg gca atg cac gtg gcl cac caa caa cac ala gaa aag	340
	Ala Leu Leu Val Ala Met His Val Ala His Gln Gln His Ile Glu Lys	
25	90 95 100	
	aaa atg cta cgg ctt gag ggg cac ggg gac ccc ctt cac ctg gaa gag	388
	Lys Met Leu Arg Leu Glu Gly His Gly Asp Pro Leu His Leu Glu Glu	
30	105 110 115	
	gta aag agg cac aag gtg cac atc tca ggg aca ctg tgg tgg acc tat	436
	Val Lys Arg His Lys Val His Ile Ser Gly Thr Leu Trp Trp Thr Tyr	
35	120 125 130 135	
	gtc atc agt gtg gtg ttc cgg ctg ctg ttt gag gct gtc ttc atg tat	484
	Val Ile Ser Val Val Phe Arg Leu Leu Phe Glu Ala Val Phe Met Tyr	
40	140 145 150	
	gtc ttc tat ctg ctc tac ccg ggc tat gcc atg gtg cgg ctg gtc aag	532
	Val Phe Tyr Leu Leu Tyr Pro Gly Tyr Ala Met Val Arg Leu Val Lys	
45	155 160 165	
	tgt gag gcc ttc ccc tgc ccc aac acg gtg gac tgc ttc gtg tcc cgc	580
	Cys Glu Ala Phe Pro Cys Pro Asn Thr Val Asp Cys Phe Val Ser Arg	
55		

	170	175	180	
5	ccc act gag aaa acc gtc ttc act gtc ttt atg ctc gcc gcc tcc ggc	628		
	Pro Thr Glu Lys Thr Val Phe Thr Val Phe Met Leu Ala Ala Ser Gly			
	185	190	195	
10	atc tgc att atc ctc aac gtg gcg gag gtg glg tac ctc atc atc cgg	676		
	Ile Cys Ile Ile Leu Asn Val Ala Glu Val Val Tyr Leu Ile Ile Arg			
15	200	205	210	215
	gcc tgt gcc cgc cgt gct cag cgc cgc tcc aat ccg ccc tcc cgc aag	724		
	Ala Cys Ala Arg Arg Ala Gln Arg Arg Ser Asn Pro Pro Ser Arg Lys			
20		220	225	230
	ggc tgc ggc ttc ggc cac cgc ctc tca cct gaa tac aag cag aat gag	772		
25	Gly Ser Gly Phe Gly His Arg Leu Ser Pro Glu Tyr Lys Gln Asn Glu			
	235	240	245	
	atc aac aag ctg ctg agc gag cag gat ggc tct ctg aaa gac ata ctg	820		
30	Ile Asn Lys Leu Leu Ser Glu Gln Asp Gly Ser Leu Lys Asp Ile Leu			
	250	255	260	
	cgc cgc agt cct ggc act ggg gcc ggg ctg gct gag aag agc gac cga	868		
35	Arg Arg Ser Pro Gly Thr Gly Ala Gly Leu Ala Glu Lys Ser Asp Arg			
	265	270	275	
40	tgc tca gcc tgc tga tgcgagtac caggcaacct cccaaccaac ccccccica	923		
	Cys Ser Ala Cys			
	280			
45	ccccaccag gcccgccct cctctccca tgcctggtag caggccctcg cctccaggg	983		
	attaccat caaaccttc cccccctt actcccttc ctgagagat cctctgcaa	1043		
50	agaccggcc ggctgggag tggggagcca cctctgcacc agggctcaag gttatgagg	1103		
	gtgtgggcaa tctctctgc ctatacctt tctctctcc tctccctgag atgagggaig	1163		

5 agatgltctg aaggigtctc caattaggaa acgtaatctt aacccccatg ctgtcaggta 1223
 cccacatttg ggagtcattg cagtggggag ggctgtgagc aagcagatg gaggaggggc 1283
 10 tctgcactgt ggaaggagaa gggaggggag ctgacctgctg tgcctgctac aaggaaaagg 1343
 aggacacatc tagggggggg gagtcttgga gggagaagca ggcagataaa tcagaglggg 1403
 15 gggtggctag ggctgcccc agtccccagt tccaaggcc tctctctctg aaaatgttac 1463
 acattaaaca ggattttaca gt 1485
 20

<210> 2

<211> 283

<212> PRT

<213> Rattus norvegicus

<400> 2

Met Asn Trp Thr Gly Leu Tyr Thr Leu Leu Ser Gly Val Asn Arg His

1 5 10 15

Ser Thr Ala Ile Gly Arg Val Trp Leu Ser Val Ile Phe Ile Phe Arg

20 25 30

Ile Met Val Leu Val Val Ala Ala Glu Ser Val Trp Gly Asp Glu Lys

35 40 45

Ser Ser Phe Ile Cys Asn Thr Leu Gln Pro Gly Cys Asn Ser Val Cys

50 55 60

Tyr Asp His Phe Phe Pro Ile Ser His Val Arg Leu Trp Ser Leu Gln

65 70 75 80

Leu Ile Leu Val Ser Thr Pro Ala Leu Leu Val Ala Met His Val Ala

85 90 95

His Gln Gln His Ile Glu Lys Lys Met Leu Arg Leu Glu Gly His Gly

100 105 110

Asp Pro Leu His Leu Glu Glu Val Lys Arg His Lys Val His Ile Ser

115 120 125

Gly Thr Leu Trp Trp Thr Tyr Val Ile Ser Val Val Phe Arg Leu Leu

130 135 140
 Phe Glu Ala Val Phe Met Tyr Val Phe Tyr Leu Leu Tyr Pro Gly Tyr
 5 145 150 155 160
 Ala Met Val Arg Leu Val Lys Cys Glu Ala Phe Pro Cys Pro Asn Thr
 165 170 175
 10 Val Asp Cys Phe Val Ser Arg Pro Thr Glu Lys Thr Val Phe Thr Val
 180 185 190
 Phe Met Leu Ala Ala Ser Gly Ile Cys Ile Ile Leu Asn Val Ala Glu
 195 200 205
 15 Val Val Tyr Leu Ile Ile Arg Ala Cys Ala Arg Arg Ala Gln Arg Arg
 210 215 220
 Ser Asn Pro Pro Ser Arg Lys Gly Ser Gly Phe Gly His Arg Leu Ser
 20 225 230 235 240
 Pro Glu Tyr Lys Gln Asn Glu Ile Asn Lys Leu Leu Ser Glu Gln Asp
 245 250 255
 25 Gly Ser Leu Lys Asp Ile Leu Arg Arg Ser Pro Gly Thr Gly Ala Gly
 260 265 270
 Leu Ala Glu Lys Ser Asp Arg Cys Ser Ala Cys
 275 280
 30

35 <210> 3
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> Description of Artificial Sequence: Insertion
 45 Sequence

<400> 3
 50 catcaccacc atcaccattg a

21

55 <210> 4
 <211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:P1

<400> 4

aacgtggcgc aggtgggtga

20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:P2

<400> 5

atggatgg tgatgatggc

20

<210> 6

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:P3

<400> 6

gggaagggtt gatggagtaa t

21

Claims

1. A rat highly sensitive to a carcinogen whose normal function in gap junction is inhibited.
2. The rat highly sensitive to a carcinogen according to claim 1, wherein the inhibition of the normal function in gap junction is an inhibition of channel function of connexon.

3. The rat highly sensitive to a carcinogen according to claim 2, wherein the inhibition of channel function of connexon is based on a deficiency of connexin function.
- 5 4. The rat highly sensitive to a carcinogen according to claim 3, wherein the deficiency of connexin function is based on a mutation of connexin 32.
- 10 5. A method for producing a rat highly sensitive to a carcinogen comprising the steps of : constructing a plasmid vector engineered to carry mutated rat connexin cDNA downstream of a promoter, and microinjecting the plasmid vector into a fertilized egg and then transplanting the fertilized egg into an oviduct.
- 15 6. The method for producing a rat highly sensitive to a carcinogen according to claim 5, wherein the promoter is an albumin promoter and the mutated rat connexin cDNA is a cDNA that encodes an amino acid sequence of rat connexin 32 wherein part of an amino acid is deleted.
- 20 7. A method for detecting a carcinogen wherein a test substance is administered to the rat highly sensitive to a carcinogen according to any one of claims 1 to 4.
8. A method for screening an anticancer substance wherein a test substance is administered to a rat made to develop a cancer by using the rat highly sensitive to a carcinogen according to any one of claims 1 to 4.
- 25 9. The method for screening an anticancer substance according to claim 8, wherein carcinogenesis of the rat highly sensitive to a carcinogen is caused by the administration of a carcinogen.

FIG. 1




FIG. 2




FIG. 3



GST-P staining






FIG. 4


Strain with high expression of the transgene, Cx32

No. of Rat No. of Foci/cm² Area of Foci/cm²

Wild	3	11.1±9.4	0.20±0.17
Tg	3	79.8±7.0 ^a	3.32±0.39 ^a

^a, Statistical significance, P<0.01

FIG. 5



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/08373

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl.⁷ A01K67/027, G01N33/15, G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl.⁷ A01K67/027, G01N33/15, G01N33/50

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

SCISEARCH (STN), EMBASE (STN), BIOSIS (STN), MEDLINE (STN), LIFESCI (STN), WPIDS (STN), CONNEXIN, CANCER, TRANSGEN?, LIVER, RAT

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	OMORI Y. et al., Involvement of Gap Junctions in Tumor Suppression: Analysis of Genetically-Manipulated Mice. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis., 02 June, 2001 (02.06.01), Vol.477, Nos. 1 to 2, pages 191 to 196	1-4, 7-8
Y	LEUBE R.E. et al., The Topogenic Fate of the Polytropic Transmembrane Proteins, Synaptophysin and Connexine, Is Determined by Their Membrane-Spanning Domains. J.Cell.Sci., 1995, Vol.108, pages 883 to 894	1-4, 7-8
Y	RAE R.S. et al., Neoplastic Phenotype of Gap-Junctional Intercellular Communication-Deficient WB Rat Liver Epithelial Cells and Its Reversal by Forced Expression of Connexin 32. Molecular Carcinogenesis, 1998, Vol.22, No.2, pages 120 to 127	1-4, 7-8

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
12 November, 2002 (12.11.02)Date of mailing of the international search report
26 November, 2002 (26.11.02)Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/08373

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	YAMASAKI H. et al., Role of Connexine (Gap Junction) Genes in Cell Growth Control and Carcinogenesis., C.R.Acad.Sci.Paris, Sciences de la vie/Life Sciences, 1999, Vol.322, Nos.2 to 3, pages 151 to 159	1-4, 7-8

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/08373

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 5 and 6
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that *no meaningful international search can be carried out, specifically:*
The sentence in claim 5 is terminated at the point of "characterized by", which makes the category of the invention unclear. Although "the rat highly sensitive to a carcinogen according to claim 5" is described in claim 6, no "rat highly sensitive to a carcinogen" is (continued to extra sheet)
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP02/08373

Continuation of Box No.I-2 of continuation of first sheet(1)

described in claim 5. Thus, the invention is unclear.